



To

Date: 30<sup>th</sup> May, 2023

The Corporate Relations Department,  
BSE Limited, Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001.

Dear Sir(s),

**Sub: Submission of Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2023**

**Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH**

\*\*\*\*\*

The Board at its meeting held today, i.e., Tuesday, 30<sup>th</sup> May, 2023, transacted inter-alia, the following businesses:

1. Financial Results:

The Board approved the Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2023. In this regard please find the enclosed:

- Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2023
- Auditor's report in respect of the Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2023
- Declaration pursuant to Regulation 33(3)(d) of Listing Regulations in terms of the audit reports with unmodified opinion.

The meeting of Board of Directors of the Company commenced at 03:00 P.M and concluded at 05:35 P.M.

The above information is also being made available at website of the Company <http://oxygentapharma.com>

This is for your information and records.

Thanking you

**For OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly known as S.S. ORGANICS LTD.)



**VANKINENI SAI SUDHAKAR**  
Managing Director  
DIN: 00733001

**OXYGENTA PHARMACEUTICAL LIMITED** (Formerly known as S.S. ORGANICS LIMITED)  
(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.  
Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.  
E-Mail id: [cs@oxygentapharma.com](mailto:cs@oxygentapharma.com), [info@oxygentapharma.com](mailto:info@oxygentapharma.com). Website: [www.oxygentapharma.com](http://www.oxygentapharma.com)

CIN: L24110TG1990PLC012038



**OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S. S. ORGANICS LIMITED )**

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Website: www.ssorganics.co.in, Email Ids: md@ssorganics.co.in, cs@ssorganics.co.in, Phone Number: 040- 23355938

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 ST MARCH 2023**


(Rupees in Lakhs except for EPS)

S. No	Particulars	Quarter Ended 31-March-2023 (Audited)	Quarter Ended 31-December-2022 (Un-Audited)	Quarter Ended 31-March-2022 (Audited)	Year ended 31-Mar-2023 (Audited)	Year ended 31-Mar-2022 (Audited)
1	Income					
	(a) Revenue from Operations	818.58	785.20	707.56	3,098.75	6,052.48
	(b) Other Income	0.10	1.68	0.32	1.78	0.45
	<b>Total income</b>	<b>818.68</b>	<b>786.88</b>	<b>707.89</b>	<b>3,100.52</b>	<b>6,052.94</b>
2	Expenses					
	(a) Cost of materials consumed	734.77	812.30	468.09	2,812.61	4,267.42
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work- in-progress and stock-in-trade	(77.76)	(195.78)	57.52	(463.48)	454.71
	(d) Direct Manufacturing Expenses	316.59	331.58	236.43	1,184.55	946.00
	(e) Employee benefit expense	41.95	27.13	7.92	112.23	33.04
	(e) Finance Costs	94.06	19.80	16.43	148.75	92.49
	(f) Depreciation and amortisation expense	85.18	40.00	38.23	205.18	159.13
	(g) Other expenses	27.72	42.59	81.01	164.53	203.71
	<b>Total expenses</b>	<b>1,222.50</b>	<b>1,077.62</b>	<b>905.64</b>	<b>4,164.36</b>	<b>6,156.51</b>
3	Profit from operations before other income and exceptional items (1-2)	(403.82)	(290.74)	(197.75)	(1,063.83)	(103.58)
4	Other income	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3+4)	(403.82)	(290.74)	(197.75)	(1,063.83)	(103.58)
6	Exceptional (expenses)/income	(5.43)	(34.31)	118.43	(73.43)	54.64
7	Profit / (Loss) from ordinary activities before tax (7+6)	(409.25)	(325.04)	(79.33)	(1,137.27)	(48.95)
8	Tax expense/(credit) - Deferred Tax	19.83	-	12.11	19.83	12.11
9	Net Profit / (Loss) from ordinary activities after tax	(429.08)	(325.04)	(91.44)	(1,157.10)	(61.05)
10	Extraordinary items (net of tax expense)	-	-	-	-	-
11	Net Profit / (Loss) for the period (11+ 12)	(429.08)	(325.04)	(91.44)	(1,157.10)	(61.05)
12	Other Comprehensive Income	-	-	-	-	-
13	Total Comprehensive Income	(429.08)	(325.04)	(91.44)	(1,157.10)	(61.05)
14	Share Profit/(loss) of associates	-	-	-	-	-
15	Minority Interest	-	-	-	-	-
16	Paid-up equity share capital (face value Rs. 10/- )	1,420.13	1,420.13	1,420.13	1,420.13	1,420.13
17.i	Earnings per share (before extraordinary items) ( of Rs.10/- each ) (not annualised):					
	(a) Basic	(3.02)	(2.29)	(0.64)	(6.36)	(0.48)
	(b) Diluted	(3.02)	(2.29)	(0.64)	(6.36)	(0.48)
17.ii	Earnings per share (after extraordinary items) ( of Rs.10/- each ) (not annualised):					
	(a) Basic	(3.02)	(2.29)	(0.64)	(6.36)	(0.48)
	(b) Diluted	(3.02)	(2.29)	(0.64)	(6.36)	(0.48)

**Notes**

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 30 May 2023 at Plot N0.43, Sy N0.55 to 58, The Park View, 1st Floor, Behind Preston Prime Mall, Lumbini Avenue, Gachibowli, Hyderabad - 500 032.
- The Company operates in a single segment and the results pertain to a single segment.
- Revenue from Operations also includes Job Work Income.
- Previous period/year figures have been regrouped and rearranged wherever considered necessary.
- Exceptional Items includes long outstanding credit and debit balances written off which are no longer payable.
- The Standalone Financial Results are reviewed by the Statutory auditors of the company as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

**For OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as S S ORGANICS LIMITED)



*Sai Sudhakar*

**SAI SUDHAKAR VANKINENI**  
Managing Director  
DIN:00733001

Place: Hyderabad  
Date: 30-May-23




**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)  
Statement of Cash Flows

	(Amount in Lakhs)	
	For the year ended 31 March 2023	For the year ended 31 March 2022
<b>I. Cash flows from operating activities</b>		
Profit before tax	(1,137.27)	(48.94)
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation of tangible assets	205.18	159.13
Amortisation of intangible assets	-	-
Finance income (including fair value change in financial instruments)	(0.50)	(0.45)
Dividend income from mutual funds	-	-
Finance costs (including fair value change in financial instruments)	148.75	92.49
Re-measurement losses on defined benefit plans	-	-
<b>Operating profit before working capital changes</b>	<b>(783.84)</b>	<b>202.24</b>
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets		
Trade receivables - Non current	(2.85)	(14.90)
Trade receivables - current	(858.38)	3.44
Inventories	(442.20)	483.06
Loans - Non current	-	(7.34)
Loans - current	-	3.87
Other financial assets - current	-	-
Other assets - current	(248.62)	118.69
Other assets - non current	(2.41)	(11.50)
Adjustment for (increase)/decrease in operating liabilities		
Trade payables	1,743.08	(909.42)
Other financial liabilities - current	54.28	(36.14)
Other current liabilities	-	-
Provisions - Non Current	19.83	12.11
<b>Cash generated from operations</b>	<b>(521.12)</b>	<b>(155.88)</b>
Interest Paid	-	-
Deferred Taxes/ Income taxes paid/charged	(19.83)	(12.11)
<b>Net cash generated from/(used in) operating activities</b>	<b>(540.95)</b>	<b>(167.99)</b>
<b>II. Cash flows from investing activities</b>		
Purchase of property, plant and equipment and intangibles (including capital work in progress)	(964.49)	(494.56)
(Investments in)/ redemption of bank deposits (having original maturity of more than three months) - net		
Dividend received on mutual funds		
Interest received (finance income)	0.50	0.45
<b>Net cash used in investing activities</b>	<b>(963.99)</b>	<b>(494.11)</b>
<b>III. Cash flows from financing activities</b>		
Proceeds from Share Capital	-	400.00
Proceeds from/(repayment of) long-term borrowings, net	1,648.76	325.66
Interest paid	(148.75)	(92.49)
<b>Net cash provided by financing activities</b>	<b>1,500.00</b>	<b>633.17</b>
<b>Net increase in cash and cash equivalents (I+II+III)</b>	<b>(4.94)</b>	<b>(28.93)</b>
Cash and cash equivalents at the beginning of the year	15.57	44.50
<b>Cash and cash equivalents at the end of the year (refer note below)</b>	<b>10.63</b>	<b>15.57</b>
<b>Note:</b>		
<b>Cash and cash equivalents comprise:</b>		
Cash on hand	0.02	3.74
Balances with banks:		
- in current accounts & Deposits	10.60	11.83
	<b>10.62</b>	<b>15.57</b>

The accompanying notes are an integral part of the financial statements.  
As per our report of even date attached

for and on behalf of the Board of Directors of  
OXYGENTA PHARMACEUTICAL LIMITED  
(Formerly Known as SS Organics Limited)  
CIN: L24110TG1990PLC012038

For and on behalf of the Board of Directors:



*Dr V Sai Sudhakar*  
Dr V Sai Sudhakar  
Managing Director

Place: Hyderabad  
Date: 30th May, 2023



**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)

**Balance Sheet as at 31 March 2023**

		Amount in Lakhs	
	Note	As at 31 March 2023	As at 31 March 2022
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	4(a)	2,791.34	1,997.71
Capital work-in-progress	4(b)	-	34.31
Intangible assets		-	-
Financial assets		-	-
Investments	5A	4.94	4.94
Loans	5B	41.97	41.97
Trade Receivables	6A	39.66	36.81
Others Financial assets	5C	47.93	45.52
Deferred tax assets, net		-	-
Other Non Current Assets		47.93	45.52
<b>Total non-current assets</b>		<b>2,925.85</b>	<b>2,161.26</b>
<b>Current assets</b>			
Inventories	7	1,170.51	728.31
Financial assets		-	-
Investments	5A	-	-
Trade receivables	6B	1,015.97	157.59
Cash and cash equivalents	8	1.75	7.15
Other balances with banks	9	8.87	8.42
Loans	5B	-	-
Others Financial assets	5C	-	-
Other current assets	10	303.52	54.90
<b>Total current assets</b>		<b>2,500.62</b>	<b>956.37</b>
<b>Total assets</b>		<b>5,426.47</b>	<b>3,117.63</b>
<b>Equity and Liabilities</b>			
<b>Equity</b>			
Equity share capital	11	1,420.13	1,420.13
Other equity	12	(6,040.13)	(4,883.04)
<b>Total equity</b>		<b>(4,620.00)</b>	<b>(3,462.91)</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Financial Liabilities			
Borrowings	13A	6,302.18	5,104.29
Lease Liabilities		-	-
Trade payables	14A	-	-
- total outstanding dues of micro enterprises and small enterprises		-	-
- total outstanding dues of creditors other than micro enterprises and small enterprises		306.51	273.43
Provisions	15A	667.72	249.94
Deferred Tax Liabilities		165.94	146.11
Other Non current liabilities			
<b>Total Non current liabilities</b>		<b>7,442.36</b>	<b>5,773.77</b>
<b>Current liabilities</b>			
Financial Liabilities			
Borrowings	13B	497.17	108.60
Lease Liabilities		-	-
Trade payables	14B	-	-
-total outstanding dues of micro enterprises and small enterprise		-	-
-total outstanding dues of Creditors otherthan micro enterprises and small enterprise		2,000.36	645.86
Other financial liabilities		-	-
Provisions	15B	52.21	11.73
Other current liabilities	16	53.38	39.59
Income tax liabilities(net)			
<b>Total current liabilities</b>		<b>2,603.12</b>	<b>805.77</b>
<b>Total liabilities</b>		<b>10,045.48</b>	<b>6,579.54</b>
<b>Total equity and liabilities</b>		<b>5,426.47</b>	<b>3,117.63</b>

The accompanying notes are an integral part of the financial statements.  
As per our report of even date

for and on behalf of the Board of Directors of  
**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)  
CIN: L24110TG1990PLC012038



For and on behalf of the Board of Directors:

*Dr V Sai Sudhakar*

Dr V Sai Sudhakar  
Managing Director

Place: Hyderabad  
Date: 30th May, 2023



Registered Office : # 4-25-7/11A A Samudralu Street Opp. Sai Ram Theatre, 1st Floor, Sec. 6, Hyderabad - 500 082



### **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the statement that give a true and fair view of the net loss and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the Companies' financial reporting process.

### **Auditor's Responsibility for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.

As part of an audit in accordance with SA's, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company





has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matters

The Financial Results include the results for the quarter ended March 31, 2023 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a Limited Review by us, as required under the Listing Regulations.

for Gowri Shankar & Associates  
Chartered Accountants  
Firm Registration No. 015625S

*S. Gowri Shankar*

Gowri Shankar Seshapu  
Partner  
M No. 234732



UDIN: 23234732 B6QERH4035





Date: 30<sup>th</sup> May, 2023

To  
The Corporate Relations Department  
Bombay Stock Exchange  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai - 400 001.

Dear Sir,

**Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Unmodified opinion**

**Ref No. Scrip Code: 524636  
DECLARATION FOR UNMODIFIED OPINION**

I, Sai Sudhakar Vankineni, Managing Director of M/s. Oxygenta Pharmaceutical Limited having its Registered office at Survey No.252/1, Aroor village, sadasivapet mandal, Medak District, Medak 502291, hereby declare that, M/s. Gowri Shankar & Associates. Chartered Accountants,, Statutory Auditors of the Company, have issued an Audit Report with Unmodified Opinion on Audited Financial Results for the Quarter and Year Ended 31<sup>st</sup> March, 2023.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015 as amended vide its circular no CIR/CFD/CMD/56/2016 dated 27<sup>th</sup> May, 2016.

Thanking You  
Yours Faithfully

For Oxygenta Pharmaceutical Limited

**Sai Sudhakar Vankineni**  
**Managing Director**  
**DIN: 00733001**

